Radiotherapy-despite being a local therapy that meanwhile is characterized by an impressively high degree of spatial accuracy-can stimulate systemic phenomena which occasionally lead to regression and rejection of non-irradiated, distant tumor lesions. These abscopal effects of local irradiation have been observed in sporadic clinical case reports since the beginning of the 20th century, and extensive preclinical work has contributed to identify systemic anti-tumor immune responses as the underlying driving forces. Although abscopal tumor regression still remains a rare event in the radiotherapeutic routine, increasing numbers of cases are being reported, particularly since the clinical implementation of immune checkpoint inhibiting agents. Accordingly, interests to systematically exploit the therapeutic potential of radiotherapy-stimulated systemic responses are constantly growing. The present review briefly delineates the history of radiotherapy-induced abscopal effects and the activation of systemic anti-tumor immune responses by local irradiation. We discuss preclinical and clinical reports with specific focus on the corresponding controversies, and we propose issues that should be addressed in the future in order to narrow the gap between preclinical knowledge and clinical experiences.
| INTRODUCTION
Together with surgery and chemotherapy, radiotherapy (RT) plays a central role in oncological treatment regimens. More than 60% of all cancer patients receive RT at one point during their medical attendance. 1 Traditionally, the efficacy of RT has been exclusively credited to its ability to induce cancer cell death and the notion that tumors are more prone to damage induced by ionizing radiation (IR) than non-malignant, normal tissues. According to the concept of the four R's of radiotherapy, repair (of IR-induced damage), reoxygenation, redistribution (to other cell cycle phases), and regeneration are the major determinants of a tissue's response toward IR. 2 Importantly, tumors and non-malignant tissues are considered to differ in these characteristics, thus forming the rationale for the use of fractionated irradiation regimens with daily fractions over a period of 3-6 weeks in the clinical routine.
It needs to be stressed that in the majority of all cases RT is applied in local settings with a high degree of spatial precision and the cardinal aim to achieve locoregional tumor control. However, there is accumulating evidence that-although applied locally-RT can induce systemic anti-tumor responses leading to regression and rejection of non-irradiated, distant tumor lesions. Collectively, these observations have been summarized under the term 'abscopal effects of RT', and meanwhile it is well accepted that immune mechanisms are the underlying driving forces. For distinct chemotherapeutics, the induction of such systemic, immune-mediated effects has been extensively analyzed by the groups of G. Kroemer and L. ZitvogeI. [3] [4] [5] The present review focuses on systemic, abscopal effects stimulated by local RT.
We will briefly outline the history of RT-induced abscopal effects as well as the RT-mediated activation of the immune system, and we will present and discuss preclinical and clinical reports with particular emphasis on their discrepancies and issues that should be considered in the future.
| THE HISTORY OF RADIOTHERAPY-INDUCED ABSCOPAL EFFECTS
It was W.C. Roentgen who announced the discovery of X-rays in November 1895, 6 published shortly afterward in 1896 7 ( Figure 1 ). Only a few months after Roentgen's discovery, E.H. Grubbe applied X-rays therapeutically to the first patient who was treated for breast cancer in January 1896. 8 Since then, RT has undergone continuous improvements, and nowadays different irradiation regimens, including conventionally fractionated RT, hypofractionated settings, and ablative RT, are clinically available. Most patients receive fractionated RT with daily doses of 1.8-2.0 Gy 5 times per week up to a total dose of 45-70 Gy. As mentioned before, the rationale for dose fractionation derives from radiobiological considerations: Repair of IR-mediated damage and regeneration mechanisms support recovery of the normal tissue between the fractions, while reoxygenation and cell cycle redistribution contribute to enhanced responsiveness of the tumor. 2 In order to reduce treatment time and the number of irradiation sessions, hypofractionated settings with fewer fractions of higher doses have been developed for cancer entities which exhibit less pronounced differences in repair, regeneration, redistribution, and reoxygenation mechanisms compared to the surrounding normal tissues. Here, patients receive fractions of more than 2.0 up to 6.0 Gy. 9, 10 For breast cancer, this is already standard of care in the UK and parts of Canada. 11, 12 Finally, ablative RT regimens with high single doses of 15 Gy and more are clinically implemented in stereotactic protocols and in intraoperative settings (IORT) where the dose is administered directly into the former tumor bed during surgery prior to wound closure. IORT is commonly used for the treatment of sarcoma, breast, pancreas, and colon cancer. [13] [14] [15] [16] Except for whole body irradiation as conditioning step for bone mar- 
| SYSTEMIC ACTIVATION OF THE IMMUNE SYSTEM BY LOCAL RADIOTHERAPY
Albeit an involvement of the immune system in tumor control was postulated already a long time ago by P. Ehrlich, 20 it took more than 50 years after Mole's report until S. Demaria and S.C. Formenti expressed in 2004 that abscopal effects induced by IR are immune-mediated 21 ( Figure 1 ). They confirmed earlier reports which had already suggested a contribution of the immune system, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and they were the first to explicitly draw this conclusion. Today, we know that the immune system represents the missing link between local RT and systemic abscopal effects, since RT is able to stimulate distinct forms of cell death that are recognized by the immune system as dangerous. [32] [33] [34] The awareness that apart from its anti-proliferative capacity, the induction of effective anti-tumor immunity contributes to the therapeutic outcome of RT may shift the focus of interest of clinicians and basic scientists in future.
Historically, RT was considered to have immunosuppressive effects and to enforce immunological tolerance. One reason for this might be that lymphocytes are among the most radiosensitive cells within the body. 35 IR reportedly can lead to lymphocytopenia, 36 although direct cytotoxic effects of RT are unlikely to account for this phenomenon, since systemic lymphocytopenia was observed upon local RT, and it persisted for several months. 37 RT can also induce the downregulation of the costimulatory surface markers CD80 and CD86 on immature dendritic cells (DCs)
thus hampering T-cell activation. 38 Nonetheless, there is accumulating evidence that RT is able to stimulate activating immune responses, andin contrast-might help to reverse the tolerogenic phenotype of many tumors. In response to RT, cells undergo different forms of cell death and/or cell stress. Depending on the irradiation dose, the cellular origin, the genetic repertoire, and the functionality of cell cycle checkpoints, diverse phenotypes of apoptosis, necrosis, mitotic catastrophe, and/ or senescence can be observed as has been reviewed elsewhere. 33, 39 Notably, the different cell death modalities clearly vary in their immunogenic potential. In order to trigger productive anti-tumor immune responses, it is generally accepted that tumor cells need to undergo forms of cell death which are sensed by the immune system as dangerous and which are accompanied by the exposure and release of danger signals and damage-associated molecular patterns (DAMPs) that attract and activate cells of the innate as well as the adaptive immune system. 5, 40 Briefly, DAMP release triggers extravasation of monocytes and promotes DC maturation and activation. Activated DCs present and crosspresent tumor antigens to naïve T cells, thus priming the establishment of adaptive, anti-tumor responses, which per se are able to counteract the irradiated tumor as well as distant, out-of-field metastases ( Figure 2 41, 42 Since cGAS in principle can sense any DNA that enters the cytosol, 43 RT-induced accumulation of cytosolic DNA fragments might also induce intrinsic type I IFN production in irradiated tumor cells. Irrespective of their cellular origin, type I IFNs stimulate antigen cross-presentation by DCs, enhanced T-cell priming in the lymph nodes, and thus the formation of irradiation-induced tumor-specific T-cell responses. 41, 44, 45 Activated T cells and natural killer cells (NK cells), in turn, secrete type II interferons (IFNγ) which enhance major histocompatibility complex (MHC) class I expression on tumor cells ultimately resulting in increased immune recognition. 46 Moreover, IFNγ was shown to modulate the tumor vasculature for improved T-cell trafficking, 46 and type I IFNs enhance T-cell recruitment by stimulating chemokine secretion. 47 Most importantly, the treatment efficacy of RT in tumor-bearing immunocompetent mice was abrogated in the absence of type I IFN signaling. 41 According to the classical concept of tumor immunoediting, established tumors have evolved mechanisms to avoid immune destruction. 48 This commonly results in a strongly immunosuppressive microenvironment and a tolerogenic phenotype of tumors. IR is able to shift this immunosuppressive microenvironment toward being more immunosupportive. 49 Via the described IFN cascade, IR enforces the presentation of an extended MHCI ligandome on tumor cells and supports the recruitment, activation, and function of DCs and T cells. 41, 44, 50, 51 This resembles a defense response upon viral infection, and it is feasible to assume that cytosolic DNA fragments generated upon IR can act as viral mimetics in this regard. Along these lines, IR meanwhile is considered as a means of in situ cancer vaccination by turning the tumor into an 'immunogenic hub' 52 ( Figure 2 ). In principle, irradiated tumor cells provide all compounds needed for a classic vaccination approach: tumor-specific antigens and adjuvants represented by DAMPs exposed and released upon IR. However, whether IR alone is able to stimulate long-lasting immunological memory as it is a prerequisite for successful vaccination remains questionable. Still, the stimulation of systemic abscopal effects by local RT and their persistence for several months endorses the idea of-at least short-term-established anti-tumor immunity. 53 
| STUDIES OF IRRADIATION-INDUCED ANTI-TUMOR IMMUNITY AND ABSCOPAL EFFECTS IN PRECLINICAL ANIMAL MODELS
Our knowledge about RT-induced anti-tumor immune mechanisms and resulting abscopal effects is largely based on preclinical model sys-
tems. In order to analyze the extent and the molecular determinants of immune-mediated, abscopal growth inhibition and tumor rejection, researchers have established and utilized a set of tumor model systems which are discussed in this section (Table 1 , Figure 3 ). Importantly, none of these models per se can be considered as undisputedly superior to any of the others; they rather differ with regard to their depth in information and exhibit unique advantages and limitations.
In principle, preclinical research in oncoimmunology employs not only transplantation models but also autochthonous models which include genetically engineered and carcinogen-induced tumors. 54, 55 Although representing tumors whose development is more realistic than that of transplantable tumors, the latter two are clearly underrepresented in experimental reports studying RT-induced anti-tumor effects, whereas heterotopic transplantation models such as subcutaneous flank, F I G U R E 2 Schematic of radiotherapy-induced abscopal effects and out-of-field lesion regression. In this example, the primary tumor was removed by surgery, and abscopal anti-tumor immunity was induced by RT of a pulmonary metastasis combined with systemic immune checkpoint blockade. The generation of an in situ vaccine by RT and immune checkpoint blockade is depicted in the right part of the scheme: Tumor antigens together with adjuvant DAMPs are released by dying tumor cells and are taken up and processed by DCs which in turn (cross-) present these tumor antigens to naïve T cells in a tumor-draining lymph node. Systemic anti-tumor immunity is achieved by activated T cells which leave the lymph node and subsequently attack metastatic tumor nodules at distant, non-irradiated sites [Colour figure can be viewed at wileyonlinelibrary.com]
T A B L E 1 Selected studies reporting abscopal, immunological effects of RT in different readout model systems. Studies are sorted according to the readout model systems (for explanation see Figure 3 ) employed. Negative abscopal effects are not listed in the weeks. 62 Another study found that the probability of tumor rejection is not only dependent on the time span between generation of antitumor immunity and rechallenge but may also be heavily diminished if a preexisting large tumor mass is still present in the organism 61 -a situation which is frequently observed when treating cancer patients with late-stage disease. Additionally, it should be noted that the capacity to reject a subcutaneous tumor rechallenge does not necessarily predict that the entire body displays a similarly high degree of immunologic memory irrespective of the site of rechallenge.
This phenomenon is known from pathogen vaccination studies 63 and is further supported by the fact that tissue-specific peculiarities of the immune system are well-known. 64 Hence, successful rejection of a tumor rechallenge at a certain time point and in a certain tissue is a very important indicator of anti-tumor immunity in preclinical model systems, but it does not always predict temporally unlimited and truly systemic anti-tumor immunity.
| Focus on abscopal effects on out-of field lesions: Model systems with secondary tumors and/or systemic tumor cell injection
The prototypical model system to study abscopal effects of RT is an animal with two subcutaneous tumors that are inoculated into both the left and the right flank or hindleg, and only one of the two tumors is irradiated (while scattered IR to the second tumor must strictly be excluded). In case of an abscopal response, growth delay of the nonirradiated tumor or even total regression is observed ( Figure 3, 3rd panel).
In a variation of this experimental setup, the secondary tumor injection is applied intravenously or into the spleen resulting in multiple disseminated tumor nodules in a specific organ such as the lungs or the liver. 29, 31, [65] [66] [67] [68] [69] The most common readout endpoint in this setting is the quantification of tumor growth in the non-irradiated organ-either by enumeration or by simply determining the weight of the tumor-infiltrated organ. 28, 29, 31, 57, 65, [68] [69] [70] In case of an abscopal response, the extent of tumor growth in the non-irradiated organ is markedly decreased. Occasionally, this model system is also employed to determine abscopal effects on artificial 'metastases' generated via disseminated distribution of intravenously injected tumor cells.
However, it should be noted that the tumor cells in this setting do not originate from a primary tumor but rather were artificially introduced by systemic injection. Hence, these 'metastases' might exhibit larger genetic and thus antigenic similarity to the primary tumor than genuine metastases do. [71] [72] [73] Therefore, it remains questionable whether an inhibition of bona fide metastasis in a (pre-)clinical situation can be deduced from results obtained in this model.
Another variant of this model uses only a single intravenous injection of tumor cells which subsequently form nodules in a certain
organ of interest such as lung or liver. 22, 23 Upon application of IR to one half of the infiltrated organ, the number of tumor nodules in the non-irradiated part of the same organ can be assessed as described above. However, the risk of unintentionally irradiating the abscopal field in this setting is higher than in those situations where the two tumor lesions are separated more clearly or with a delay in time.
| Focus on abscopal effects on distant metastases: Model systems with autochthonous metastases
Some tumor cell lines such as the murine mammary carcinoma 4T1
and Lewis lung carcinoma cells, spontaneously metastasize to distant organs even after subcutaneous implantation. 24, 26, 30, [74] [75] [76] [77] [78] [79] [80] This property can be exploited to measure abscopal effects on metastatic growth after IR of the primary tumor ( Figure 3 , 4th panel). The severity of the metastatic process is eventually quantified as described above. In contrast to model systems using 'experimental metastases' introduced by intravenous or intrasplenic injection of tumor cells, this setup allows to study the abscopal inhibition of bona fide metastases after RT and thus also accounts for the fact that metastatic lesions might already have acquired different antigenic properties, thus distinguishing them from their tumor of origin. [71] [72] [73] Importantly, to ascertain the detection of abscopal effects on distant metastases (instead of the primary tumor's incapacity to give rise to metastatic cells), therapy of the primary tumor needs to be started at a time point when micrometastases have already formed in the respective organ. However, since this experimental detail is not considered by all authors whose work is discussed here, it cannot be excluded that some of them merely detected anti-tumor effects on the primary tumor prior to dissemination instead of truly abscopal effects on existing metastases.
| ENHANCEMENT OF RADIOTHERAPY-INDUCED ANTI-TUMOR IMMUNITY: IMMUNOMODULATORS, CHEMOTHERAPY, AND EXOGENOUS TUMOR CELL VACCINES
Even before 2004, when Demaria et al. 21 identified the immune system as the key mediator of abscopal anti-tumor effects, researchers in this field had already focused on combining RT with immunomodulation in order to strengthen the immune response against out-of-field and/or metastatic tumor lesions of various origins. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] 80 Since then, a plethora of-in the broadest sense-immunomodulatory substances has been tested for their capacity to strengthen systemic anti-tumor immune responses or to unleash abscopal effects in the first place.
Despite their heterogeneity, the majority of these substances can be summarized into groups which share common properties.
Earlier in vivo studies on RT-induced anti-tumor immunity and abscopal effects frequently tested the co-administration of cytokines.
By the 1980s, the T-cell proliferation stimulating activity of interleukin (IL)-2 had already been demonstrated in preclinical and clinical cancer immunotherapy, 81, 82 and this cytokine was consequently used in preclinical studies to explore its synergy with RT in murine models of melanoma, lymphoma, colorectal, mammary, and renal cell carcinoma. 22, 23, 25, 27, 28, 69 In order to reduce the severe side effects of systemic IL-2 application, peri-or intratumoral administration was successfully employed. anti-PD-1 antibodies with RT evoked abscopal tumor regression in murine melanoma and in mammary, renal, and colon carcinoma models. 65, 74, 76, 88, 94, 97, 105 Interestingly, studies using a triple therapy with RT and simultaneous blockade of the PD-1/PD-L1-axis as well as CTLA-4
showed conflicting results with regard to the additional effect of combined immune checkpoint blockade on abscopal tumor responses. 94, 97 Apart The aim of combining local RT with any type of immunomodulatory substance as discussed above is to enhance and improve the in situ cancer vaccination effects of RT ( Figure 2 ). Along these lines, several preclinical studies also tested exogenous tumor vaccination procedures in order to stimulate systemic anti-tumor immunity. 49, 61, 84, 96, 108, 109, 112 Interestingly, the vaccination effect of ex vivo-irradiated tumor cells (mixed with varying adjuvants) was rather weak, and in some reports it was even counterproductive with regard to different endpoints, including rejection of a tumor challenge and regression of an abscopal tumor upon RT, 49, 96, 109, 112 whereas evidence for much more potent anti-tumor immunity was observed if the irradiated tumor cell vaccine was genetically modified to produce either GM-CSF alone or GM-CSF, IL-2, and IFNγ. 108 Last but not least, some authors also tested different chemotherapeutics in combination with RT and analyzed their impact on abscopal tumor regression. 86, 110, 128 It is well-known that the induction of cancer cell death by distinct chemotherapeutics such as anthracyclines, cyclophosphamide, and oxaliplatin can activate strong anti-tumor immune responses, whereas other substances like mitomycin C fail to do so. 3, [113] [114] [115] [116] [117] Notably, we were unable to find a study which utilized any chemotherapeutic agent in order to enhance the abscopal effects of RT in fully immunocompetent animals. Instead, one group reported that abscopal effects on lung metastases were nearly completely abolished upon combination of RT with paclitaxel in murine mammary carcinoma. 110 Since combinations of RT and various chemothera- 70 In contrast, other groups reported that anti-tumor immunity induced by ablative doses of ≥15 Gy was more potent than after fractionated treatments in murine melanoma and colon carcinoma, 44,49 whereas Dewan et al. 95 found that hypofractionation (3×8 Gy) was superior both to a single dose of 20 Gy and a regimen using more and smaller fractions (5×6 Gy). In part, these results are conflicting, but it needs to be mentioned that the terms 'highdose', 'low-dose', 'fractionated', and 'hypofractionated' RT are used inconsistently in preclinical reports, thus leading to misinterpretations when comparing studies from different researchers. Nevertheless, it is remarkable that the majority of all studies discussed here employed (high) single-dose IR or hypofractionated regimens with relatively large doses (≥6 Gy) to induce abscopal effects.
Apart from the efficacy of RT itself, the capacity of combined treatment approaches to synergize with IR may also have substantial impact on the therapeutic outcome: As discussed above, most studies demonstrated an enhanced therapeutic effect of RT when combined with additional therapeutics, whereas RT alone was either ineffective or inferior to the combined modality approaches tested. However, this is further complicated by the fact that not only timing and concentration of additional therapeutics but also their site of application may largely influence the establishment of anti-tumor immunity. For instance, abscopal tumor regression upon RT plus IL-2 administration was reported for systemic, peritumoral, or intratumoral IL-2 application, respectively, making it even more complex to identify the best-suited therapy. both reports revealed that RT is able to increase the intratumoral Tcell receptor diversity in melanoma and colon cancer models. 97, 105 Interestingly, the two studies employed completely different RT regimens (1×20 Gy vs 5×2 Gy), thus proving that T-cell expansion after RT
is not restricted to a specific irradiation regimen. Furthermore, Dovedi et al. not only analyzed T-cell clonality in irradiated but also in abscopal lesions. In their study, fractionated RT, albeit inducing a polyclonal Tcell response in the irradiated tumor, was unable to diversify the T-cell receptor repertoire at the abscopal site. Importantly, the limited systemic effects of fractionated RT on T-cell expansion were overcome by additional PD-1 blockade leading to strong diversification of the expanded T-cell clones at both tumor sites. This was paralleled by higher complete regression rates of non-irradiated tumors as compared to abscopal tumors in animals receiving RT alone. 105 The results further suggested that hypofractionated or ablative RT in combination with PD-1 blockade might even be more potent in this regard-an issue that needs to be addressed in greater detail. Nevertheless, the two studies clearly underline the importance of clonal intratumoral T-cell expansion, and it is evident that further studies with focus on the T-cell receptor repertoire will improve our understanding of T cell-mediated Furthermore, two groups reported on the tumor suppressor protein p53 as a mediator of RT-stimulated abscopal effects. Murine lung tumors and fibrosarcomas regressed upon excessive irradiation of distant healthy tissue in wildtype but not in p53 mutant mice. 127 The mechanisms underlying this effect were not further dissected, but an involvement of massive inflammatory cytokine production was proposed.
Another study employed human colorectal xenografts with wildtype or p53 mutant tumors in nude mice, thus excluding any influence of T cells. 118 Apart from this report, abscopal effects on human pancreatic xenograft tumors were also observed in T cell-deficient mice. An early study by Kaplan and Murphy found an increase in pulmonary metastasis of subcutaneously implanted mammary carcinoma upon IR, 132 and similar effects were described more than half a century later in a study by Camphausen et al. 131 using lung and fibrosarcoma tumors. At first sight, these reports appear to be in stark contrast to those of various other authors who showed a therapeutic benefit of primary tumor RT on distant metastasis. However, it is important to stress that both Kaplan Abscopal effects could be regarded as special variants of spontaneous tumor regression resulting from radiobiological influences.
| CLINICAL EXPERIENCES WITH ABSCOPAL EFFECTS OF RADIOTHERAPY
While in some early descriptions, the true existence of a malignant lesion that was treated remains questionable, later reports are more precise and are mostly confirmed by histological examinations. 136 A systematic analysis of such cases published in the first half of the 20th century shows-apart from a steady increase in the number of reports-that some cancer entities seem to lead to spontaneous regression more frequently than others. 136 Additionally, a trend concerning relevant trigger factors was determined and included immunological factors, irradiation, infection, and others. 136 
| CASE REPORTS
Over the last decades, several case reports of RT-induced abscopal effects have been published. A systematic search of the respective literature reveals that sometimes the definition of abscopal effects is not restricted to out-of-field responses toward RT only but also to other types of therapy, 138 whereas in other cases abscopal effects stimulated by RT are described as 'spontaneous tumor regression', thus rendering comprehensive analyses challenging. [139] [140] [141] At first sight, the majority of patients with RT-induced abscopal effects are of advanced age, suffer from progressed and metastasized cancer, and are treated in palliative settings ( 
| MECHANISTIC CONSIDERATIONS
The therapeutic accessibility of tumor cells is one major challenge in cancer treatment, especially when trying to protect the normal healthy tissue. granted for several cancer entities, including metastatic melanoma, RCC, non-small cell lung cancer (NSCLC), and others (Figure 1) .
Although overall response rates of Ipilimumab monotherapy in metastatic melanoma are relatively low with approximately 11%, responding patients show clearly improved survival rates, and a subgroup of long-term survivors has been described. 93 Nevertheless, Ipilimumab treatment is often limited by severe toxic effects, including rash, colitis, diarrhea, pruritus, dermatitis, uveitis, nephritis, and hepatitis-synoptically (auto-)immune-related symptoms which can be life-threatening in the worst case. 150, 151 In order to counteract these adverse effects, immunosuppressive agents such as steroids, Infliximab and Mycophenolate mofetil are applied. 152 
| Combinatorial strategies: Synergism and timing
Considering their closely related modes of action, the question of combining different immune checkpoint blockers arises immediately.
As their individual targets differ but exert similar functions, their combination might provide improved therapeutic outcome at lower doses.
In fact, trials of combined modality approaches with Ipilimumab and Nivolumab reported prolonged survival in the combined treatment arms. However, this was linked to increased occurrence of adverse events, particularly high-grade toxicity. 156 Therefore, the search for appropriate synergistic combination partners with acceptable total toxicity continues. Once more, RT represents an interesting candidate in this regard. Intriguingly, in some case reports where palliative patients often progressed under immune checkpoint blocking therapy alone, local and abscopal responses were observed when radiotherapy was added. [157] [158] [159] A fundamental difference between most of the radiotherapeutic regimens implemented in the clinical routine and the presented case reports of RT-induced abscopal effects is the volume of tumor and/ or metastasis mass that is irradiated. As case reports often concern palliative settings, the entire lesion is irradiated. Thus, upon RT an enormous amount of tumor antigen most likely is released compared to postoperative, adjuvant RT which is standard for the majority of cases in the clinical routine. In one case report, a biopsy sample of the irradiated kidney tumor was subjected to histological examination after manifestation of the abscopal effect. 141 Excessive necrosis was 
Mediastinal lesion
After RT DC, dendritic cell; f, female; fr, fraction; IFN, interferon; IL, interleukin; LN, lymph node; m, male; n.a., not available; RT, radiotherapy; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy; *, performed after abscopal effect and therefore not specified.
T A B L E 2 (Continued)
| OBSERVATIONS IN DIFFERENT CANCER ENTITIES
As already mentioned, systematic analyses of the available case reports imply difficulties and limitations when aiming at extracting a common denominator which should be considered for future treatment approaches in order to fully exploit the therapeutic potential of RT-induced abscopal effects. Case reports from various cancer entities with known differences in immunogenicity have been published, letting it appear reasonable to discuss them separately (Table 2) . We have also tried to visualize the reported abscopal effects with regard to cancer entity, irradiated site, irradiation regimen, and site of the described abscopal effects in a schematic drawing (Figure 4 ).
| Melanoma
Ipilimumab and other immune checkpoint blockers have reached clinical approval for the treatment of metastatic melanoma due to very convincing trial results. 93, 99, 156 Subsequently, they have been described in several case reports of RT-induced abscopal effects, [159] [160] [161] [162] [163] [164] and the combination of RT plus checkpoint inhibition is subject of current clinical trials 157, 165, 166 (Table 3) . Obviously, checkpoint inhibition powerfully enforces the occurrence of RT-induced abscopal effects. However, this seems to be strongly dependent on the cancer entity, as in case of advanced prostate cancer no comparable observations have been described. 167 Melanoma is a cancer with high mutation frequency, and this might well be responsible for the fact that stronger immune responses can be triggered in melanoma than in other cancer entities. 168, 169 A clinical observation which underlines this increased anti-melanoma activity is the development of vitiligo upon, e.g. Pembrolizumab treatment. 170 Vitiligo is an acquired autoimmune disease against active melanocytes resulting in depigmented areas of skin at different sites of the body and was shown to go along with better treatment outcome. 170 Like abscopal responses after RT, in these cases vitiligo is a systemic immune effect caused by immunotherapy. In a case report on abscopal effects in metastatic melanoma, seroreactivity to melanocyte antigens was analyzed and melanomaassociated antigen A3 showed seropositivity after radiotherapy which increased even further with administration of Ipilimumab. 161 Some trials have been set up in order to investigate the frequencies of RTinduced abscopal effects in melanoma and show impressive results.
Between 25 and 52% of patients with advanced melanoma undergoing RT plus checkpoint inhibition displayed abscopal effects, and compared to patients without abscopal effects, they had significantly prolonged overall survival times. 157, 165, 166 Although these studies have their limitations, the reported frequencies of abscopal effects are quite remarkable. Yet, these observations could be linked to the particular immunogenicity of malignant melanoma and may not be entirely transferable to other cancer entities.
| Lymphoma
Another particular field of RT-induced abscopal effects is lymphoma.
In 1969, M.P. Nobler was the first to describe an abscopal effect in malignant lymphoma (giant follicle type) and to provide careful Therefore, generalization to other cancer entities might be rather limited.
| Diverse solid tumors
RT-mediated abscopal effects have been reported also for diverse solid tumors. Nevertheless, two entities appear to dominate: RCC and HCC. An interesting detail in two of the collected case reports is that progressive disease was observed at one site, while abscopal regression was simultaneously described at different other sites of the body. 146, 172 This implies that the susceptibility of some metastases to abscopal responses seems to be different than that of others, and it needs to be clarified which factors are responsible in this scenario.
| Brain lesions
Due to its particular anatomy and the blood-brain barrier, the brain's accessibility for drugs and cells of the immune system underlies spe- there is a number of melanoma cases with brain metastases. [161] [162] [163] 173 Intriguingly, to our knowledge, so far no case report has shown abscopal brain metastasis regression when peripheral lesions were irradiated. On the contrary, two reports showed peripheral abscopal responses upon brain irradiation (whole brain RT as well as stereotactic radiosurgery with and without additional immune checkpoint blockade). 162, 163 Two other reports presented similar cases, where abscopal effects appeared after brain radiotherapy. 161, 173 However, it needs to be considered that these patients had already received previous RT treatments in other body regions, and it cannot be specified if the abscopal effects were primarily due to brain irradiation or the preceding RT. Although these reports have their limitations, it appears that abscopal effects can be stimulated by irradiation of brain lesions, whereas irradiation of peripheral nodules vice versa fails to stimulate abscopal lesion regression in the brain.
| CELLULAR AND MOLECULAR PARAMETERS IN PATIENTS WITH RADIOTHERAPY-INDUCED ABSCOPAL EFFECTS
Although patients with RT-induced abscopal effects represent a rather heterogeneous group, they exhibit common features-not only clinically, but also on a cellular and molecular level. However, since abscopal responses are generally not expected a priori, all analyses were performed retrospectively, and systematic prospective evaluations are not available.
In the well-known case report by Postow et al., 159 
| CLINICAL TRIALS AND RETROSPECTIVE ANALYSES WITH FOCUS ON ABSCOPAL RESPONSES
Although RT-mediated abscopal effects are rather rare phenomenona, a number of case reports as well as common characteristics among them suggest that distinct factors contribute to their appearance. Yet, the mechanisms behind this remain elusive, and more in-depth analyses are needed in this regard. GM-CSF was chosen as an agent which can stimulate DC activation and cross-presentation. However, the authors argue that T-cell exhaustion might limit long-term antitumor immunity, and therefore suggest systematic trial approaches to evaluate immune checkpoint inhibition in combination with RT. 179 This is the focus of several ongoing clinical trials (Table 3) 
| THE PERSISTING GAP BETWEEN CLINICAL AND PRECLINICAL OBSERVATIONS
For decades, abscopal tumor regression has been an extremely rare and nearly mysterious phenomenon which was observed in very few patients, and only some but by far not all determinants of this effect have been elucidated by now. With the advent of immunotherapies, the view on RT-induced abscopal effects has gradually changed, but many clinicians still do not consider distant tumor regression in response to local RT as a reasonable therapeutic aim but rather as an incidental side benefit in a very limited set of patients. In contrast, our knowledge about the mediators in this context is largely based on preclinical animal models, where IR-dependent out-of-field tumor regression can be generated reproducibly with a given treatment. As discussed before, these preclinical models fundamentally contributed to our understanding of RT-stimulated abscopal responses. However, several aspects in this field are still not sufficiently addressed and other findings lack translational relevance. Most importantly, we are about to reach a point where it is no longer sufficient to simply demonstrate once more that abscopal effects can be generated in a given mouse model. Instead, the time is overdue to test novel therapeutics and treatment approaches for their efficacy in combination with RT to stimulate abscopal effects using clinically relevant treatment regimens in animal models which closely mimic the clinical situation in the patient. well as parallel effects raise the question of how to ideally combine these therapeutic measures. Unfortunately, only limited data are available in this regard, and more studies focusing on optimizing the therapeutic sequence are needed.
Considering that the great advances in modern cancer therapy were only possible due to gradually improving the interplay between surgery, RT, chemotherapy, molecularly targeted therapy, and immunotherapy, it is already evident that this will by no means question the crucial importance of any of the involved disciplines but rather shed light on the issue of their optimal therapeutic interplay with the aim of achieving the best therapeutic outcome for every individual patient.
We are convinced that our understanding of RT-induced abscopal effects will increase rendering their therapeutic potential exploitable on a regular basis if, on the one hand, preclinical researchers address the aforementioned clinically relevant problems in suitable animal models with clinically relevant treatment regimens and if, on the other hand, clinicians carefully reflect these findings in order to fine-tune and to reconsider the clinically established treatment protocols. Besides, bioinformatic approaches have been proposed as a means to improve our understanding of abscopal tumor regression by integrating preclinical and clinical data into mathematical models. 189, 190 However, due to the obvious limitations in biological and clinical information available at present, it is questionable whether these models will offer any reliable conclusions for the clinic at this early stage. issue that will also be addressed in these trials is the identification of predictive and follow-up markers which will help to select suitable subgroups of patients and can serve for proper monitoring ( Figure 5 ).
| CONCLUSIONS
Abscopal effects of RT have a long-standing history and have made their way through anecdotal case reports and preclinical evaluation. 
